Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ARAravive, Inc. logo

Aravive, Inc. (ARAV)

NASDAQ Global Select · Currency in USD
$0.04 ▼ -0.01 (-13.39%)
At close: Jan 26, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.05
Open
$0.04
Day's Range
$0.04 – $0.05
52 Week Range
$0.04 – $2.46
Volume
4,040,076
Avg. Volume
2,162,145
Market Cap
$2.95M
Beta (5Y Monthly)
2.19
PE Ratio (TTM)
--
EPS (TTM)
-$2.22
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$0.25

Profile: Aravive, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
23
CEO
Fredric N. Eshelman

Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma.

Earnings

DateEst.Actual
Mar 20, 2024-$0.08-$0.46Miss
Nov 9, 2023-$0.24-$0.10Beat
Aug 21, 2023-$0.30-$0.12Beat
May 11, 2023-$0.33-$0.66Miss
Mar 15, 2023-$0.33-$0.46Miss
Nov 10, 2022-$0.64-$0.51Beat

Analyst view

Consensus price target
$0.25 ▲ +523.4%
Range $0.25 – $0.25
Rating: Hold
Buy 44% · Hold 50% · Sell 6%

Get free alerts on ARAV and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.